Cargando…

Mucosal Healing and Clinical Efficacy of Adalimumab in Small Intestinal Crohn’s Disease (SIMCHA Study): Final Results From a Prospective, Open-Label, Single-Arm Study

BACKGROUND: Endoscopic healing is a key treatment target in inflammatory bowel disease; few data are available on the clinical and endoscopic efficacy of biological therapy in upper gastrointestinal Crohn’s disease. This study aimed to investigate small bowel mucosal healing and clinical efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Wetwittayakhlang, Panu, Verdon, Christine, Starr, Michael, Drügg Hahn, Gustavo, Golovics, Petra A., Bessissow, Talat, Afif, Waqqas, Wild, Gary, Bitton, Alain, Lakatos, Peter L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Turkish Society of Gastroenterology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441132/
https://www.ncbi.nlm.nih.gov/pubmed/37162506
http://dx.doi.org/10.5152/tjg.2023.22527
_version_ 1785093310075895808
author Wetwittayakhlang, Panu
Verdon, Christine
Starr, Michael
Drügg Hahn, Gustavo
Golovics, Petra A.
Bessissow, Talat
Afif, Waqqas
Wild, Gary
Bitton, Alain
Lakatos, Peter L.
author_facet Wetwittayakhlang, Panu
Verdon, Christine
Starr, Michael
Drügg Hahn, Gustavo
Golovics, Petra A.
Bessissow, Talat
Afif, Waqqas
Wild, Gary
Bitton, Alain
Lakatos, Peter L.
author_sort Wetwittayakhlang, Panu
collection PubMed
description BACKGROUND: Endoscopic healing is a key treatment target in inflammatory bowel disease; few data are available on the clinical and endoscopic efficacy of biological therapy in upper gastrointestinal Crohn’s disease. This study aimed to investigate small bowel mucosal healing and clinical efficacy of adalimumab therapy by video capsule endoscopy in patients with endoscopically active upper gastrointestinal Crohn’s disease. METHODS: This prospective, open-label, single-arm study included Crohn’s disease patients with moderate–severe endoscopic proximal small bowel involvement, defined by a Lewis score >790. Patients were treated with adalimumab monotherapy for 24 weeks. Co-primary outcomes were endoscopic healing, defined as Lewis score <350, and endoscopic response, defined as >50% decrease in Lewis score. Secondary outcomes included clinical (Harvey–Bradshaw index <4) and biomarker remission (fecal calprotectin <250 μg/g, and C-reactive protein <5 mg/L). RESULTS: A total of 59 Crohn’s disease patients were screened; 17 patients have met eligibility criteria and were enrolled. Endoscopic healing was observed in 8 patients (47.1%) and endoscopic response in additional 5 patients (29.4%) at 24 weeks. Median Lewis score was significantly decreased compared to baseline (1912 vs. 337, P = .0005). Eleven of 13 patients (84.6%) with clinical activity achieved clinical remission (baseline: 13/17 vs. week 24: 2/17, P < .0001). Nine of 10 patients with elevated C-reactive protein achieved normal C-reactive protein after treatment and the median C-reactive protein significantly decreased from 7.4 to 1.6 mg/L, P = .032. In contrast, no change was observed in fecal calprotectin pre- and posttreatment. CONCLUSIONS: Adalimumab induced endoscopic healing and clinical remission in patients with active small bowel Crohn’s disease, with approximately half of the patients achieving endoscopic healing.
format Online
Article
Text
id pubmed-10441132
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Turkish Society of Gastroenterology
record_format MEDLINE/PubMed
spelling pubmed-104411322023-08-22 Mucosal Healing and Clinical Efficacy of Adalimumab in Small Intestinal Crohn’s Disease (SIMCHA Study): Final Results From a Prospective, Open-Label, Single-Arm Study Wetwittayakhlang, Panu Verdon, Christine Starr, Michael Drügg Hahn, Gustavo Golovics, Petra A. Bessissow, Talat Afif, Waqqas Wild, Gary Bitton, Alain Lakatos, Peter L. Turk J Gastroenterol Original Article BACKGROUND: Endoscopic healing is a key treatment target in inflammatory bowel disease; few data are available on the clinical and endoscopic efficacy of biological therapy in upper gastrointestinal Crohn’s disease. This study aimed to investigate small bowel mucosal healing and clinical efficacy of adalimumab therapy by video capsule endoscopy in patients with endoscopically active upper gastrointestinal Crohn’s disease. METHODS: This prospective, open-label, single-arm study included Crohn’s disease patients with moderate–severe endoscopic proximal small bowel involvement, defined by a Lewis score >790. Patients were treated with adalimumab monotherapy for 24 weeks. Co-primary outcomes were endoscopic healing, defined as Lewis score <350, and endoscopic response, defined as >50% decrease in Lewis score. Secondary outcomes included clinical (Harvey–Bradshaw index <4) and biomarker remission (fecal calprotectin <250 μg/g, and C-reactive protein <5 mg/L). RESULTS: A total of 59 Crohn’s disease patients were screened; 17 patients have met eligibility criteria and were enrolled. Endoscopic healing was observed in 8 patients (47.1%) and endoscopic response in additional 5 patients (29.4%) at 24 weeks. Median Lewis score was significantly decreased compared to baseline (1912 vs. 337, P = .0005). Eleven of 13 patients (84.6%) with clinical activity achieved clinical remission (baseline: 13/17 vs. week 24: 2/17, P < .0001). Nine of 10 patients with elevated C-reactive protein achieved normal C-reactive protein after treatment and the median C-reactive protein significantly decreased from 7.4 to 1.6 mg/L, P = .032. In contrast, no change was observed in fecal calprotectin pre- and posttreatment. CONCLUSIONS: Adalimumab induced endoscopic healing and clinical remission in patients with active small bowel Crohn’s disease, with approximately half of the patients achieving endoscopic healing. Turkish Society of Gastroenterology 2023-06-01 /pmc/articles/PMC10441132/ /pubmed/37162506 http://dx.doi.org/10.5152/tjg.2023.22527 Text en © Copyright 2023 authors https://creativecommons.org/licenses/by/4.0/ Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. (https://creativecommons.org/licenses/by/4.0/)
spellingShingle Original Article
Wetwittayakhlang, Panu
Verdon, Christine
Starr, Michael
Drügg Hahn, Gustavo
Golovics, Petra A.
Bessissow, Talat
Afif, Waqqas
Wild, Gary
Bitton, Alain
Lakatos, Peter L.
Mucosal Healing and Clinical Efficacy of Adalimumab in Small Intestinal Crohn’s Disease (SIMCHA Study): Final Results From a Prospective, Open-Label, Single-Arm Study
title Mucosal Healing and Clinical Efficacy of Adalimumab in Small Intestinal Crohn’s Disease (SIMCHA Study): Final Results From a Prospective, Open-Label, Single-Arm Study
title_full Mucosal Healing and Clinical Efficacy of Adalimumab in Small Intestinal Crohn’s Disease (SIMCHA Study): Final Results From a Prospective, Open-Label, Single-Arm Study
title_fullStr Mucosal Healing and Clinical Efficacy of Adalimumab in Small Intestinal Crohn’s Disease (SIMCHA Study): Final Results From a Prospective, Open-Label, Single-Arm Study
title_full_unstemmed Mucosal Healing and Clinical Efficacy of Adalimumab in Small Intestinal Crohn’s Disease (SIMCHA Study): Final Results From a Prospective, Open-Label, Single-Arm Study
title_short Mucosal Healing and Clinical Efficacy of Adalimumab in Small Intestinal Crohn’s Disease (SIMCHA Study): Final Results From a Prospective, Open-Label, Single-Arm Study
title_sort mucosal healing and clinical efficacy of adalimumab in small intestinal crohn’s disease (simcha study): final results from a prospective, open-label, single-arm study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441132/
https://www.ncbi.nlm.nih.gov/pubmed/37162506
http://dx.doi.org/10.5152/tjg.2023.22527
work_keys_str_mv AT wetwittayakhlangpanu mucosalhealingandclinicalefficacyofadalimumabinsmallintestinalcrohnsdiseasesimchastudyfinalresultsfromaprospectiveopenlabelsinglearmstudy
AT verdonchristine mucosalhealingandclinicalefficacyofadalimumabinsmallintestinalcrohnsdiseasesimchastudyfinalresultsfromaprospectiveopenlabelsinglearmstudy
AT starrmichael mucosalhealingandclinicalefficacyofadalimumabinsmallintestinalcrohnsdiseasesimchastudyfinalresultsfromaprospectiveopenlabelsinglearmstudy
AT drugghahngustavo mucosalhealingandclinicalefficacyofadalimumabinsmallintestinalcrohnsdiseasesimchastudyfinalresultsfromaprospectiveopenlabelsinglearmstudy
AT golovicspetraa mucosalhealingandclinicalefficacyofadalimumabinsmallintestinalcrohnsdiseasesimchastudyfinalresultsfromaprospectiveopenlabelsinglearmstudy
AT bessissowtalat mucosalhealingandclinicalefficacyofadalimumabinsmallintestinalcrohnsdiseasesimchastudyfinalresultsfromaprospectiveopenlabelsinglearmstudy
AT afifwaqqas mucosalhealingandclinicalefficacyofadalimumabinsmallintestinalcrohnsdiseasesimchastudyfinalresultsfromaprospectiveopenlabelsinglearmstudy
AT wildgary mucosalhealingandclinicalefficacyofadalimumabinsmallintestinalcrohnsdiseasesimchastudyfinalresultsfromaprospectiveopenlabelsinglearmstudy
AT bittonalain mucosalhealingandclinicalefficacyofadalimumabinsmallintestinalcrohnsdiseasesimchastudyfinalresultsfromaprospectiveopenlabelsinglearmstudy
AT lakatospeterl mucosalhealingandclinicalefficacyofadalimumabinsmallintestinalcrohnsdiseasesimchastudyfinalresultsfromaprospectiveopenlabelsinglearmstudy